chevron_leftBack
As of 13 June 2026, FibroBiologics, Inc. has a market cap of $6.82M USD, ranking #43179 globally and #5529 in the United States.
It ranks #3819 in the Healthcare sector, and #750 in the Biotechnology industry.
Key Stats
Market Cap
$6.82MUSD
Enterprise Value
$4.6MUSD
EBITDA (TTM)
-$16.41MUSD
Net Income (TTM)
-$18.65MUSD
PB Ratio
0.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Peter O’Heeron
open_in_new
Employees
15
Founded
2021
IPO
31 Jan 2024
Website
fibrobiologics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.7% | -16% | -67% | -82% | -84% | -94% |
News
Loading...
FBLG Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
FBLG
ISIN: US31573L2043
Shares Out.:
Shares Outstanding:
5.209M1
Shares Float:
4.394M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.31 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
3M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
2M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
404K%
|
-
|
|
NYSE: IQV
|
$26.3B
385K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
367K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
266K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
701K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
657K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
621K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
620K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
412K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
376K%
|
-
|
chevron_leftBack